Phosphoramidite

Innovassynth and Actylis partner to address Nucleic Acid Supply Chain Vulnerabilities

Retrieved on: 
Thursday, May 4, 2023
Science, Research, Health, Chemicals, Plastics, Genetics, Logistics, Supply Chain Management, Transport, Manufacturing, GMP, Custom, DNA, Partnership, Process, Speciality chemicals, Medication, RNA, Chemistry, CDMO, N-Acetylgalactosamine, Partner, Materials science, LNA, R, Phosphoramidite, Organometallics, Fine chemical, Nucleoside

Innovassynth, India, is a Custom Development & Manufacturing Organization (CDMO) and a trusted partner to Pharma & Drug Discovery, Life Sciences, Diagnostics, and Material Science companies worldwide.

Key Points: 
  • Innovassynth, India, is a Custom Development & Manufacturing Organization (CDMO) and a trusted partner to Pharma & Drug Discovery, Life Sciences, Diagnostics, and Material Science companies worldwide.
  • Innovassynth offers end-to-end manufacturing and a transparent supply chain for Phosphoramidites and a variety of nucleic acid reagents, which is a compelling proposition to customers lacking supply chain diversity.
  • Actylis provides local and global distribution in the US and Europe through strategically located warehouses, supply chain and sales offices in over ten countries.
  • Due to its techno commercial expertise, global sales and distribution network, Actylis has emerged as the trusted partner of choice.

Global Phosphoramidite Market Report 2022: Increasing Synthetic Nucleotide Applications in Therapeutics Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 11, 2022
Biotechnology, Genetics, Health, Merck, Thermo Fisher Scientific, Prevalence, Science, Oligonucleotide, Laboratory, CAGR, Phosphoramidite, Synthetic biology, Hospital, Genetic engineering, Research, Polymerase chain reaction, Region, Chemistry, DNA, Engineering, Fine chemical

The "Phosphoramidite Market - A Global and Country Level Analysis: Focus on Type, End User, and Region - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Phosphoramidite Market - A Global and Country Level Analysis: Focus on Type, End User, and Region - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • The global phosphoramidite market is projected to reach $2,062.9 million by 2032 from $900.3 million in 2021, at a CAGR of 7.78% during the forecast period 2022-2032.
  • The global phosphoramidite market is in the rapidly evolving and dynamic stage, which opens ample opportunities for life sciences companies.
  • The companies operating in the global phosphoramidite market are now focusing more on high-quality and customized options.

OliX Pharmaceuticals and AM Chemicals Announce Exclusive Licensing and Supply Agreement for GalNAc-Conjugation Technology for Liver Targeting

Retrieved on: 
Monday, March 30, 2020
American Motors Corporation, Chrysler, Phosphoramidite, RNA interference, Chemistry, Economy of the United States

Under the agreement, AMC will supply a selection of GalNAc-modified phosphoramidites and solid supports to OliX Pharmaceuticals.

Key Points: 
  • Under the agreement, AMC will supply a selection of GalNAc-modified phosphoramidites and solid supports to OliX Pharmaceuticals.
  • AMC will also provide support for RNA synthesis, for which AMC is entitled to receive upfront milestone and royalty payments.
  • "We are pleased to be entering into this partnership with OliX Pharmaceuticals," saidAndrei Guzaev, President and Chief Scientific Officer of AMC.
  • "OliX Pharmaceuticals, with its demonstrated leadership in the field of RNAi technology, is an ideal partner for extending the application of AM Chemicals GalNAc-modified phosphoramidites in the pharmaceutical industry.